52 results
8-K
EX-99.1
NVCR
NovoCure Ltd
2 May 24
Novocure Reports First Quarter 2024 Financial Results
7:01am
reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific
8-K
EX-99.1
NVCR
NovoCure Ltd
27 Mar 24
Regulation FD Disclosure
7:00am
, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its
8-K
EX-99.1
rr9fsjj6cns0
22 Feb 24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
7:06am
8-K
EX-99.1
97a4yu
18 Jan 24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
7:01am
8-K
EX-99.1
qo9n ffdgjy37rrjmag
9 Jan 24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
7:00am
8-K
EX-99.1
m4d7c
8 Jan 24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
7:10am
8-K
EX-99.1
tlkfk srf
4 Jan 24
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4:10pm
8-K
EX-99.1
m6089ijl9xfok aw
28 Nov 23
Regulation FD Disclosure
7:30am
8-K
EX-99.1
gljnpwz
26 Oct 23
Novocure Reports Third Quarter 2023 Financial Results
7:03am
8-K
EX-99.1
grxny
28 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
292gjieafnqo
27 Jul 23
Novocure Reports Second Quarter 2023 Financial Results
7:03am
8-K
EX-99.1
6foos poeho
21 Jul 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
n0th1 tszd
6 Jun 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
6qz4u2 qd
4 May 23
Novocure Reports First Quarter 2023 Financial Results
7:02am
8-K
EX-99.1
i66uxp71u9s
26 Apr 23
Regulation FD Disclosure
10:03am